Annual Results Presentation 2022

Celebrating 25 years of Continuous Growth and Improvement in Animal Health and Welfare

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.

Our Purpose is the sustainable improvement of global animal health and welfare.

For more information please visit www.dechra.com

Companion Animal Products (CAP)

Species: Dogs and cats.

Key therapeutic sectors: Endocrinology, dermatology, analgesia and anaesthesia, antibiotics, cardiovascular and critical care.

Equine

Species: Horses and ponies.

Key therapeutic sectors: Lameness and pain management.

Food producing Animal Products (FAP)

Species: Poultry, pigs and an increasing presence in cattle.

Key therapeutic sectors: Water soluble antibiotics, vaccines, locomotion (lameness) and pain management.

Nutrition

Species: Dogs and cats.

Species: Dogs and cats.

Key therapeutic sectors: Our pet diets are available to support the wellbeing of cats and dogs with numerous therapeutic conditions, such as allergies, obesity, heart and kidney disease.

Operational Highlights

Strategic Growth Drivers

Portfolio Focus

a b c

  • Strong organic growth in all key markets
  • Growth delivered in all therapeutic segments

Geographic Expansion

• International portfolio strengthened through numerous product approvals

  • Established a sales & marketing business unit in South Korea, the world's eighth largest CAP market

Pipeline Delivery

  • Positive progress in diabetes drugs developed with Akston Biosciences
  • Pipeline strengthened through own innovation and acquisition

Acquisition

  • Successfully completed two material company acquisitions post year-end: Piedmont and Med-Pharmex
  • Also executed numerous bolt-on product acquisitions to complement existing equine and CAP portfolios

®

3

Operational Highlights

Strategic Enablers

Technology

• Excellent progress on major IT projects: new quality document management system and upgraded Manufacturing ERP system

  • Increased investment in digital communication capabilities

Manufacturing

and Supply

  • Ongoing investment across our network of sites
  • Consistently high levels of stock availability
  • Continue to migrate more production in-house

People

  • New appointments at Board and SET level
  • Investment in talent development to support future organic growth
  • Remain a Living Wage (or equivalent) employer globally

Environmental, Social and Governance

  • Strong progress in developing our ESG strategy, metrics and targets
  • Publication of inaugural standalone Sustainability Report

®

4

Financial Highlights

Strong organic revenue and profit growth supplemented by acquisitions

Revenue Growth

  • Increase of 13.8% to £681.8 million
  • Organic revenue growth of 11.8%, with North America particularly strong at 21.3%

Underlying

EBIT Growth

  • Increase of 9.4% to £174.3 million
  • Operating margin higher than pre-pandemic levels of 2020 financial year

Operating Cash

Generation

  • Strong cash generation of £163.3 million representing cash conversion of 93.7%

Shareholder

Value

  • Underlying diluted EPS increase of 14.0% to 120.84 pence
  • Full year dividend increased by 10.8% to 44.89 pence

Growth is at CER

®

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Dechra Pharmaceuticals plc published this content on 05 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 September 2022 10:19:02 UTC.